Cue Biopharma, Inc.

How big is Cue Biopharma, Inc.?

As of Jun 18, Cue Biopharma, Inc. has a market capitalization of 43.71 million and reported net sales of 8.00 million with a net profit of -40.59 million over the latest four quarters.

As of Jun 18, Cue Biopharma, Inc. has a market capitalization of 43.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 8.00 million, while the sum of net profit for the same period is -40.59 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 17.50 million and total assets of 32.19 million.

What does Cue Biopharma, Inc. do?

Cue Biopharma, Inc. is a development-stage immunotherapy company focused on creating biologics to target T cell subsets for cancer and autoimmune disease treatments. As of March 2025, it has a market cap of $43.71 million, with no net sales and a net loss of $12 million.

Overview:<BR>Cue Biopharma, Inc. is a development-stage immunotherapy company focused on developing biologics to selectively modulate disease-relevant T cell subsets for the treatment of cancer and autoimmune diseases, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market classification.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 43.71 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.94 <BR>Return on Equity: -616.78% <BR>Price to Book: 6.64 <BR><BR>Contact Details:<BR>Address: 21 Erie St, CAMBRIDGE MA: 02139-4260 <BR>Tel: ['1 617 9492680', '1 617 9492602'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.cuebiopharma.com/

Should I buy, sell or hold Cue Biopharma, Inc.?

Who are in the management team of Cue Biopharma, Inc.?

As of March 2022, the management team of Cue Biopharma, Inc. includes Dr. Frank Morich (Independent Chairman), Mr. Daniel Passeri (CEO and Director), and several Independent Directors: Ms. Tamar Howson, Mr. Frederick Driscoll, Dr. Aaron Fletcher, Dr. Cameron Gray, and Dr. Peter Kiener. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Cue Biopharma, Inc. includes the following individuals:<BR><BR>- Dr. Frank Morich, who serves as the Independent Chairman of the Board.<BR>- Mr. Daniel Passeri, who is the Chief Executive Officer and a Director.<BR>- Ms. Tamar Howson, who is a Director.<BR>- Mr. Frederick Driscoll, who is an Independent Director.<BR>- Dr. Aaron Fletcher, who is an Independent Director.<BR>- Dr. Cameron Gray, who is an Independent Director.<BR>- Dr. Peter Kiener, who is also an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Cue Biopharma, Inc. overvalued or undervalued?

As of August 8, 2023, Cue Biopharma, Inc. is considered overvalued and risky due to its high Price to Book Value of 7.34 and negative EV to EBIT and EV to EBITDA ratios, significantly underperforming its peers and the S&P 500 with a year-to-date return of -33.02%.

As of 8 August 2023, Cue Biopharma, Inc. has moved from a grade of does not qualify to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued given its high Price to Book Value of 7.34, a concerning EV to EBIT of -1.02, and an EV to EBITDA of -1.09, all reflecting significant financial distress. <BR><BR>In comparison to its peers, Theseus Pharmaceuticals, Inc. has a fair valuation with an EV to EBITDA of 0.3754, while Sangamo Therapeutics, Inc. also carries a risky valuation with an EV to EBITDA of -2.0816. The stark contrast in valuation metrics suggests that Cue Biopharma is not only underperforming relative to its peers but is also facing severe operational challenges. Additionally, Cue Biopharma's stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, reinforcing the notion that the stock is overvalued.

Is Cue Biopharma, Inc. technically bullish or bearish?

As of September 3, 2025, Cue Biopharma, Inc. is in a mildly bearish trend with key indicators showing bearish signals, underperforming the S&P 500 with a year-to-date return of -33.02% and a five-year decline of -95.78%.

As of 3 September 2025, the technical trend for Cue Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators including a bearish daily moving average and a bearish weekly RSI. While the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by bearish readings from Bollinger Bands and a mildly bearish OBV on the weekly chart. <BR><BR>In terms of performance, Cue Biopharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -33.02% compared to the S&P 500's 12.22%, and a significant decline of -95.78% over the past five years against the S&P's 96.61% gain.